Noetik, a San Francisco, CA-based AI drug discovery company focused on precision therapeutics in immuno-oncology, has raised $14 million in seed funding.
SaaS Investors
The round was led by DCVC, with participation from Zetta Venture Partners, 11.2 Capital, Catalio Capital Management, and others.
Founded in 2010, DCVC is a venture capital firm headquartered in Palo Alto, California. The firm seeks to invest in the crypto, anti-terror and security, climate resilience, cybersecurity, smart agriculture, space access and intelligence, deep tech, and biotechnology sectors
Noetic Use of Funds
The company plans to use the funding to support data generation efforts and further develop machine learning methods. The funding will also be used to expand Noetik’s team in machine learning, computational biology, and cancer immunology.
About Noetik
Noetik is an AI-native biotechnology company that developed a tissue profiling platform that combines self-supervised learning with spatial biology to address problems in cancer immunology. By harnessing the potential of self-supervised learning and human multimodal data, Noetik aims to discover better precision immunotherapies. The company is based in San Francisco, CA.
Funding Details
Company: Noetik, Inc.
Raised: $14.0M
Round: Seed Round
Funding Month: September 2023
Lead Investors: DCVC
Additional Investors: Zetta Venture Partners, 11.2 Capital, Catalio Capital Management
Company Website: https://www.noetik.ai/
Software Category: AI-Drug Discovery
Source: https://www.businesswire.com/news/home/20230907509972/en/